DE69936730D1 - Pharmazeutische aerosolzubereitung, die hfa227 und hfa 134a enthält - Google Patents

Pharmazeutische aerosolzubereitung, die hfa227 und hfa 134a enthält

Info

Publication number
DE69936730D1
DE69936730D1 DE69936730T DE69936730T DE69936730D1 DE 69936730 D1 DE69936730 D1 DE 69936730D1 DE 69936730 T DE69936730 T DE 69936730T DE 69936730 T DE69936730 T DE 69936730T DE 69936730 D1 DE69936730 D1 DE 69936730D1
Authority
DE
Germany
Prior art keywords
hfa
preparation containing
pharmaceutical aerosol
aerosol preparation
inhaler
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69936730T
Other languages
English (en)
Other versions
DE69936730T2 (de
Inventor
David Lewis
David Ganderton
Brian Meakin
Paolo Ventura
Gaetano Brambilla
Raffaella Garzia
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chiesi Farmaceutici SpA
Original Assignee
Chiesi Farmaceutici SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiesi Farmaceutici SpA filed Critical Chiesi Farmaceutici SpA
Publication of DE69936730D1 publication Critical patent/DE69936730D1/de
Application granted granted Critical
Publication of DE69936730T2 publication Critical patent/DE69936730T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE69936730T 1998-11-25 1999-11-22 Lösungsaerosolzusammensetzungen, die HFA227 und HFA 134a enthalten Expired - Lifetime DE69936730T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT1998MI002558A IT1303788B1 (it) 1998-11-25 1998-11-25 Formulazioni di aerosol medicinali.
ITMI982558 1998-11-25
PCT/EP1999/008959 WO2000030607A1 (en) 1998-11-25 1999-11-22 PHARMACEUTICAL AEROSOL COMPOSITION CONTAINING HFA 227 AND HFA 134a

Publications (2)

Publication Number Publication Date
DE69936730D1 true DE69936730D1 (de) 2007-09-13
DE69936730T2 DE69936730T2 (de) 2008-04-30

Family

ID=11381136

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69936730T Expired - Lifetime DE69936730T2 (de) 1998-11-25 1999-11-22 Lösungsaerosolzusammensetzungen, die HFA227 und HFA 134a enthalten

Country Status (22)

Country Link
US (2) US6713047B1 (de)
EP (1) EP1133277B1 (de)
JP (1) JP2002530316A (de)
KR (1) KR100794060B1 (de)
CN (1) CN1177582C (de)
AT (1) ATE368450T1 (de)
AU (1) AU770529B2 (de)
BR (1) BR9916865A (de)
CA (1) CA2352483C (de)
CY (1) CY1106904T1 (de)
DE (1) DE69936730T2 (de)
DK (1) DK1133277T3 (de)
ES (1) ES2289832T3 (de)
IL (1) IL143293A0 (de)
IT (1) IT1303788B1 (de)
MA (1) MA26763A1 (de)
NO (1) NO330195B1 (de)
NZ (1) NZ511923A (de)
PT (1) PT1133277E (de)
TR (1) TR200101442T2 (de)
WO (1) WO2000030607A1 (de)
ZA (1) ZA200104220B (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010031244A1 (en) * 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
DZ2947A1 (fr) * 1998-11-25 2004-03-15 Chiesi Farma Spa Inhalateur à compteur de dose sous pression.
IT1303788B1 (it) * 1998-11-25 2001-02-23 Chiesi Farma Spa Formulazioni di aerosol medicinali.
US6739333B1 (en) 1999-05-26 2004-05-25 Boehringer Ingelheim Pharma Kg Stainless steel canister for propellant-driven metering aerosols
US6315985B1 (en) * 1999-06-18 2001-11-13 3M Innovative Properties Company C-17/21 OH 20-ketosteroid solution aerosol products with enhanced chemical stability
IT1313553B1 (it) 1999-07-23 2002-09-09 Chiesi Farma Spa Formulazioni ottimizzate costituite da soluzioni di steroidi dasomministrare per inalazione.
FR2798290B1 (fr) 1999-09-11 2003-09-12 Glaxo Group Ltd Formulation pharmaceutique de propionate de fluticasone
US20030032632A1 (en) * 1999-12-24 2003-02-13 Crispps Leslie Alan Pharmaceutical aerosol formulation of salmeterol and fluticasone propionate
IT1317720B1 (it) * 2000-01-07 2003-07-15 Chiesi Farma Spa Dispositivo per la somministrazione di aerosol dosati pressurizzati inpropellenti idrofluoroalcani.
IT1318514B1 (it) * 2000-05-12 2003-08-27 Chiesi Farma Spa Formulazioni contenenti un farmaco glucocorticosteroide per iltrattamento di patologie broncopolmonari.
SK286694B6 (sk) * 2000-05-22 2009-03-05 Chiesi Farmaceutici S.P.A. Aerosólový farmaceutický prostriedok
US20060257324A1 (en) 2000-05-22 2006-11-16 Chiesi Farmaceutici S.P.A. Pharmaceutical solution formulations for pressurised metered dose inhalers
GB2367011A (en) * 2000-08-26 2002-03-27 Glaxo Group Ltd Metered dose inhaler for salmeterol
ES2222294T3 (es) * 2001-07-02 2005-02-01 Chiesi Farmaceutici S.P.A. Formulacion optimizada de tobramicina para administracion en forma de aerosol.
EP1340503A1 (de) * 2002-03-01 2003-09-03 CHIESI FARMACEUTICI S.p.A. Lösung Aerosol Formulierung von Estern von 3,17-dihydroxy Oestratrien-Derivaten zur Lungenverabreichung
EP1415647A1 (de) * 2002-10-23 2004-05-06 CHIESI FARMACEUTICI S.p.A. Langwirkende beta-2-Agonisten in ultrafeiner Formulierung
EP1340492A1 (de) * 2002-03-01 2003-09-03 CHIESI FARMACEUTICI S.p.A. Aerosolformulierungen zur pulmonalen Verabreichung von Arzneimitteln mit systemischer Wirkung
PT3494995T (pt) * 2002-03-01 2020-03-30 Chiesi Farm Spa Formulação superfina de formoterol
US7311894B2 (en) 2002-03-28 2007-12-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg HFA suspension formulations containing an anticholinergic
ES2275778T3 (es) * 2002-06-06 2007-06-16 Chiesi Farmaceutici S.P.A. Solubilizacion de farmacos en propulsores de hfa mediante emulsiones.
EP1452179A1 (de) * 2003-02-27 2004-09-01 CHIESI FARMACEUTICI S.p.A. Neue Kombination von hochwirksamer langzeitiger Beta-2-Agonist und einem Corticosteroid
MXPA05009920A (es) 2003-03-20 2005-11-04 Boehringer Ingelheim Pharma Formulacion para un inhalador con dosis medida que emplea hidrofluoroalcanos como propulsores.
EP1915985A1 (de) 2003-03-20 2008-04-30 Boehringer Ingelheim Pharmaceuticals Inc. Formulierung für einen Dosierinhalator mit Hydrofluoralkanen als Treibstoffen
US20080118442A1 (en) * 2003-09-10 2008-05-22 Map Pharmaceuticals, Inc. Aerosol Formulations for Delivery of Dihydroergotamine to the Systemic Circulations Via Pulmonary Inhalation
AR041873A1 (es) * 2003-10-30 2005-06-01 Pablo Cassara Srl Lab Una formulacion farmaceutica en aerosol adecuada para la inhalacion oral o nasal que contienen glucocorticoides en solucion estable al almacenamiento; un metodo para estabilzar formulaciones y uso de un agente estabilizante
EP1595531A1 (de) * 2004-05-13 2005-11-16 CHIESI FARMACEUTICI S.p.A. Stabile Arzneimittellösung für Druckdosierinhalatoren
KR20070000476A (ko) * 2004-02-27 2007-01-02 키에시 파르마슈티시 엣스. 피. 에이. 압축화 계량된 도스흡입용 안정된 약제용액 제제
CN1583170A (zh) * 2004-06-10 2005-02-23 安米 用于抗病毒抗耐药菌的人溶菌酶药物及其制法
JP5209963B2 (ja) 2004-07-02 2013-06-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 噴霧剤としてｔｇ２２７ｅａ又はｔｇ１３４ａを含有するエアロゾル懸濁製剤
DE102006017320A1 (de) 2006-04-11 2007-10-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Aerosolsuspensionsformulierungen mit TG 227 ea oder TG 134 a als Treibmittel
EP2011534A1 (de) * 2007-07-03 2009-01-07 CHIESI FARMACEUTICI S.p.A. Aktuator für einen Inhalator für abgemessene Dosen
WO2011150441A1 (en) * 2010-06-03 2011-12-08 Wholesome Biopharm Pty Ltd Medical aerosol formulation comprising ribavirin
CN103052378A (zh) * 2010-08-03 2013-04-17 奇斯药制品公司 包含磷酸二酯酶抑制剂的药物制剂
WO2014205030A1 (en) * 2013-06-19 2014-12-24 Map Pharmaceuticals, Inc. Pulmonary administration of rotigotine
WO2016170518A1 (en) 2015-04-24 2016-10-27 Glenmark Specialty S.A. Pharmaceutical compositions comprising arformoterol and glycopyrronium
CN114796166A (zh) * 2021-01-29 2022-07-29 北京远大九和药业有限公司 一种含有萜烯类挥发油的气雾剂及其制备方法
CN114522143A (zh) * 2022-02-22 2022-05-24 暨南大学 用于吸入气雾剂的低制冷效应复合抛射剂及其制备方法和应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH89518A (de) * 1919-03-22 1921-06-01 Croning Johannes Der Türdicke entsprechend einstellbares Gehäuse für Zylinderschlösser.
US3095355A (en) * 1961-10-12 1963-06-25 Revlon Aerosol composition
US3860618A (en) * 1967-08-08 1975-01-14 Philip Saxton Hartley Chromone
US5192528A (en) * 1985-05-22 1993-03-09 Liposome Technology, Inc. Corticosteroid inhalation treatment method
GB8828477D0 (en) * 1988-12-06 1989-01-05 Riker Laboratories Inc Medical aerosol formulations
JP2769925B2 (ja) 1990-10-18 1998-06-25 ミネソタ マイニング アンド マニュファクチャリング カンパニー ベクロメタゾン１７，２１ジプロピオネートを含んで成るエアロゾル製剤
MX9203481A (es) * 1990-10-18 1992-07-01 Minnesota Mining & Mfg Formulaciones.
US5190029A (en) * 1991-02-14 1993-03-02 Virginia Commonwealth University Formulation for delivery of drugs by metered dose inhalers with reduced or no chlorofluorocarbon content
US5653961A (en) * 1995-03-31 1997-08-05 Minnesota Mining And Manufacturing Company Butixocort aerosol formulations in hydrofluorocarbon propellant
TR199701167T1 (xx) 1995-04-14 1998-03-21 Glaxo Wellcome Inc. Albuterol i�in �l��lm�� doz inhaleri.
GB9612297D0 (en) 1996-06-11 1996-08-14 Minnesota Mining & Mfg Medicinal aerosol formulations
EP0914143A1 (de) * 1996-07-08 1999-05-12 Rhone-Poulenc Rorer Limited Medizinische aerosollösungsformulierungen mit cyclosporin-a
GB9620187D0 (en) * 1996-09-27 1996-11-13 Minnesota Mining & Mfg Medicinal aerosol formulations
DK1014943T3 (da) * 1997-02-05 2002-10-14 Jago Res Ag Medicinske aerosolformuleringer
US6126919A (en) * 1997-02-07 2000-10-03 3M Innovative Properties Company Biocompatible compounds for pharmaceutical drug delivery systems
GB2326334A (en) * 1997-06-13 1998-12-23 Chiesi Farma Spa Pharmaceutical aerosol compositions
IT1303788B1 (it) * 1998-11-25 2001-02-23 Chiesi Farma Spa Formulazioni di aerosol medicinali.
US6004537A (en) 1998-12-18 1999-12-21 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol
SK286694B6 (sk) * 2000-05-22 2009-03-05 Chiesi Farmaceutici S.P.A. Aerosólový farmaceutický prostriedok
EP1415647A1 (de) * 2002-10-23 2004-05-06 CHIESI FARMACEUTICI S.p.A. Langwirkende beta-2-Agonisten in ultrafeiner Formulierung
PT3494995T (pt) * 2002-03-01 2020-03-30 Chiesi Farm Spa Formulação superfina de formoterol
EP1340492A1 (de) * 2002-03-01 2003-09-03 CHIESI FARMACEUTICI S.p.A. Aerosolformulierungen zur pulmonalen Verabreichung von Arzneimitteln mit systemischer Wirkung

Also Published As

Publication number Publication date
CA2352483A1 (en) 2000-06-02
IT1303788B1 (it) 2001-02-23
ES2289832T3 (es) 2008-02-01
ZA200104220B (en) 2002-05-23
PT1133277E (pt) 2007-10-09
DK1133277T3 (da) 2007-12-27
KR100794060B1 (ko) 2008-01-10
EP1133277B1 (de) 2007-08-01
NO20012517L (no) 2001-07-23
NZ511923A (en) 2003-10-31
AU1555300A (en) 2000-06-13
NO20012517D0 (no) 2001-05-22
IL143293A0 (en) 2002-04-21
DE69936730T2 (de) 2008-04-30
ITMI982558A1 (it) 2000-05-25
BR9916865A (pt) 2001-11-13
CN1177582C (zh) 2004-12-01
JP2002530316A (ja) 2002-09-17
CY1106904T1 (el) 2012-05-23
US20040184993A1 (en) 2004-09-23
WO2000030607A1 (en) 2000-06-02
EP1133277A1 (de) 2001-09-19
NO330195B1 (no) 2011-03-07
CN1331581A (zh) 2002-01-16
CA2352483C (en) 2009-01-20
AU770529B2 (en) 2004-02-26
US6713047B1 (en) 2004-03-30
KR20010080560A (ko) 2001-08-22
TR200101442T2 (tr) 2002-05-21
MA26763A1 (fr) 2004-12-20
WO2000030607A8 (en) 2001-03-22
ATE368450T1 (de) 2007-08-15

Similar Documents

Publication Publication Date Title
DE69936730D1 (de) Pharmazeutische aerosolzubereitung, die hfa227 und hfa 134a enthält
Steckel et al. In vitro evaluation of dry powder inhalers I: drug deposition of commonly used devices
MXPA02011414A (es) Formulaciones farmaceuticas en solucion estable para inhaladores presurizados con medicion de dosis.
TNSN04148A1 (en) Aerosol formulations for pulmonary administration of medicaments to produce a systemic effect
Maggi et al. Influence of the moisture on the performance of a new dry powder inhaler
BR9406908A (pt) Composição farmacêutica dispositivo inalador processo para administração sistema de um polipeptideo farmaceuticamente ativo para a fabricação e preparação de uma composição farmacêutica e uso de um agente de melhoramento na preparação de uma preparação de po seco inalavel
NZ334149A (en) Pharmaceutical aerosol composition containing an active material, a propellant containing a hydrofluoroalkane and a cosolvent and a low volatility component
IS4178A (is) Lyfjablanda til innöndunar sem inniheldur insúlín
EA200100338A1 (ru) Способ и устройство для введения действующего вещества в виде аэрозоли в легкие пациента
BR9911351A (pt) Formulações farmacêuticas para aerossóis com duas ou mais substâncias ativas
DE69205177D1 (de) Pharmazeutische Aerosolformulierung.
AR009370A1 (es) UNA COMPOSICION FARMACEUTICA EN AEROSOL ADECUADA PARA LA ADMINISTRACION DE BUDESONIDA, UN PRODUCTO FARMACEUTICO QUE LA CONTIENE, UN METODO PARAADMINISTRAR BUDESONIDA Y USO DE UNA MEZCLA DE HFA 134a Y HFA 227
SK286139B6 (sk) Zariadenie na podávanie odmeraných dávok aerosólov
HUP0302036A2 (hu) Glükokortikoidot tartalmazó készítmény bronchopulmonális betegségek kezelésére
JP2004529108A5 (de)
YU87902A (sh) Stabilne farmaceutske formulacije rastvora za inhalatore odmerene doze pod pritiskom
GEP20053649B (en) Stable Pharmaceutical Solution Formulations for Pressurised Metered Dose Inhalers

Legal Events

Date Code Title Description
8364 No opposition during term of opposition